Almost four million people miss their medical appointments every year due to a lack of reliable transportation. To address this challenge, Lyft has been working with healthcare organizations since 2016 to get patients in need to and from their medical appointments.
This week on Tuning Into The C-Suite Briana Contreras spoke with Dr. Scott Hayworth, president and CEO of New York-based CareMount Medical. In this interview, the two discussed the importance of patients staying in contact with their doctors for the sake of reducing public health risks and to discuss ongoing care options with them.
Principals of DeltaSigma, LLC , Don Hall, M.P.H., and Sherry Rohlfing provide Managed Healthcare Executive an opinion piece on how managed care organizations can address COVID-19 transmission.
Drug for a specific Duchenne muscular dystrophy mutation is only the second drug approved for the mutation.
Celiac disease was linked with a greater likelihood to be diagnosed with a mood disorder, ADHD, or an eating disorder.
Real-world evidence from 67 patients recently found benefits for those with diabetic macular edema who switched to Eylea from Lucentis.
The drug’s indication for marginal zone lymphoma (MZL) may not be approved until February 2021.
Whether the OCM has worked out is debatable, but it has apparently encouraged the use of biosimilar versions of filgrastim.
Selections from weekend health care coverage, August 17, 2020.
U.S. healthcare was gearing up for a rebound that includes telehealth. But then the pandemic surged back.
Yale-developed, NBA-funded saliva test costing $10 per test could make frequent testing of asymptomatic people feasible.
Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.
In this part two of two series, Senior Editor Peter Wehrwein and Associate Editor Briana Contreras chat with Keely Macmillan, senior vice president of policy and solutions management at Archway Health. The trio discusses the Value in Health Care Act of 2020, which would make some important changes to the Medicare Shared Savings Programs ACOs, the largest CMS ACO program.
In this part one of two series, Senior Editor Peter Wehrwein and Associate Editor Briana Contreras chat with Keely Macmillan, senior vice president of policy and solutions management at Archway Health. The trio discusses the Value in Health Care Act of 2020, which would make some important changes to the Medicare Shared Savings Programs ACOs, the largest CMS ACO program.
Deloitte, a consulting firm, recently released new data on consumer behaviors towards healthcare and how those behaviors changed as a result of the COVID-19 pandemic in a survey.
The physician-led communication training program is now available through a virtual-only experience as health care organizations adapt to the changing environment surrounding COVID-19.
A majority of executives believe technology has become an inseparable part of the human experience in a recent survey. However, a bit more than half of those execs said advancements in new technologies and scientific innovations are positioned to disrupt the industry.
Excess deaths associated with the two pandemics are in the same ballpark during New York City peaks.
Dr. Karen Vloedman shares her learnings that will help inform best practices to assist payers and provider groups when preparing for and navigating the CoVID-19 pandemic.
In this week's episode, Briana Contreras spoke with Suzet McKinney, CEO of the Illinois Medical District and an Adjunct Instructor at Harvard University's T.H. Chan School of Public Health. The two discussed the role of social determinants when promoting health and health equity and most importantly why and how racism is a public health issue.
Harris ended up proposing a moderate Medicare for all plan modeled on the Medicare Advantage choice that seniors now have.
Physical therapy or the regular physical activity that successful treatment of MSK disorders makes possible helps reduce the risk of many chronic conditions including type 2 diabetes, heart disease and hypertension, dementia, and mental health issues like depression and anxiety.
Colcrys and Copaxone are among the exceptions.
Evrysdi is only the second drug approved to treat the rare disease.
Botco.ai’s AI-powered intelligent chat solution automatically addresses questions regarding COVID-19, scheduling visits, franchising and more.
Olinvyk is the first new chemical entity in this IV drug class in decades.
Researchers reviewed the evidence of the association between vitamin D and multiple sclerosis.
A recent study found 64% of patients with psoriatic arthritis who had tried at least one biologic stayed with Cosentyx for the entire study period.
Next generation PBMs like Flipt and RxSense are challenging the "old guard" PBMs that control three-quarters of the market.
